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See Focus, pages 969–970Background & Aims: Hepatocellular carcinoma (HCC) is one of
the most common malignancies worldwide. Although hepatec-
tomy and transplantation have signiﬁcantly improved survival,
there is no effective chemotherapeutic treatment for HCC and
its prognosis remains poor. Sustained activation of telomerase
is essential for the growth and progression of HCC, suggesting
that telomerase is a rational target for HCC therapy. Therefore,
we developed a thymidine analogue pro-drug, acycloguanosyl-
50-thymidyltriphosphate (ACV-TP-T), which is speciﬁcally acti-
vated by telomerase in HCC cells and investigated its anti-tumour
efﬁcacy.
Methods: First, we veriﬁed in vitro whether ACV-TP-T was a tel-
omerase substrate. Second, we evaluated proliferation and apop-
tosis in murine (Hepa1-6) and human (Hep3B, HuH7, HepG2)
hepatic cancer cells treated with ACV-TP-T. Next, we tested the
in vivo treatment efﬁcacy in HBV transgenic mice that spontane-
ously develop hepatic tumours, and in a syngeneic orthotopic
murine model where HCC cells were implanted directly in the
liver.Journal of Hepatology 20
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the pro-drug was actively metabolized in liver cancer cells by tel-
omerase to release the active form of acyclovir. Alterations in cell
cycle and apoptosis were observed following in vitro treatment
with ACV-TP-T. In the transgenic and orthotopic mouse models,
treatment with ACV-TP-T reduced tumour growth, increased
apoptosis, and reduced the proliferation of tumour cells.
Conclusions: ACV-TP-T is activated by telomerase in HCC cells
and releases active acyclovir that reduces proliferation and
induces apoptosis in human and murine liver cancer cells. This
pro-drug holds a great promise for the treatment of HCC.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY license.Introduction
Hepatocellular carcinoma (HCC) is the primary malignancy of
hepatocytes and the most frequent solid tumour of the liver. Half
a million cases occur annually in the world making it the ﬁfth
most common malignancy in men and the ninth in women [1].
Hepatocarcinogenesis is a multistep process, involving genetic
and epigenetic events that accumulate during chronic liver dis-
eases. The extent of hepatic dysfunction limits therapeutic
options for HCC and the prognosis of patients with this tumour
remains dismal, as the average survival from the time of diagno-
sis of unresectable HCC is measured in months [2]. Therefore, in
this dramatic scenario, HCC is an attractive target for the identi-
ﬁcation of new chemotherapeutic agents.
The current trend in research on anti-cancer drugs is to
exploit particular traits or hallmarks that are unique to cancer
cells. Despite the fact that cancers display a great heterogeneity
in clinical behaviour, most human tumours, including HCC, share
a limited set of acquired capabilities that deﬁne the malignant
state [3,4]. Emerging insights into the biology and molecular14 vol. 61 j 1064–1072
Table 1. Cytotoxicity (based on ATP concentration) and anti-proliferative
activity (based on [3H] thymidine incorporation) of ACV-TP-T in four different
hepatic cancer cell lines and one normal colon cell line in comparison with
telomerase activity.
Cell lines Viability
(IC50 μM)
DNA synthesis 
(IC50 μM)
Telomerase 
activity
Mouse
Hepa 1-6 >1000 3 260
Human
HuH7 1000 30 364
Hep-G2 1000 15 410
Hep-3B 1000 8 735
18CO >1000 >1000 0
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signalling pathways of HCC cells have led to the identiﬁcation of
several potential new targets for intervention and the advent of
numerous targeted therapies for the treatment of this otherwise
lethal tumour. The recent use of Sorafenib, a multikinase inhibi-
tor, is a step forward in the treatment of advanced HCC [5,6],
and represents the beginning of a new horizon in the molecular
targeted therapy of HCC [7]. Another particularly interesting tar-
get is the unlimited replicative potential of cancer cells via the
activation of a telomere maintenance mechanism, which is a
key step to ensure expansive tumour growth [8].
Telomerase is a ribonucleoprotein complex containing the
reverse transcriptase enzyme hTERT that adds repetitive DNA
sequences to telomeres, preventing telomere shortening and con-
sequently cell death. Telomerase activity in the adult is present
only in a few proliferating cell types, including germ cells, bone
marrow stem cells, and epithelial basal cells [9]. In contrast to
normal cells, malignant cells from a large variety of human
tumours contain active telomerase, which plays a key role in cel-
lular immortalization [10]. In HCC, telomerase reactivation has
been detected in over 80% of cases and gene expression analyses
have shown that hTERT can be included in sets of selected genes
that provide molecular signatures, used for the diagnosis and the
management of hepatic nodules [11,12]. Moreover, hTERT mRNA
levels increase during progression of HCCs and correlate with the
transition between low- and high-grade dysplastic nodules [13].
Therefore, telomere maintenance and hTERT are considered
potential targets for anti-cancer drug development.
The well-known antiviral agent acyclovir (ACV) is a nucleotide
analogue acting as a DNA chain terminator [14], mainly used in
the treatment of herpes virus infection. The high selectivity of
ACV for virus-infected cells is due to the presence of viral thymi-
dine kinases (TK) that speciﬁcally and selectively phosphorylate
ACV to acyclovir monophosphate (ACV-MP). Human enzymes,
guanylate monophosphate (GMP) kinase and nucleoside
diphosphate (NDP) kinase, then further phosphorylate ACV-MP
to di- (ACV-DP) and triphosphate (ACV-TP), and the latter is
incorporated into DNA, arresting its replication [15] (Supplementary
Fig. 1). On this basis, adenoviruses carrying the herpesvirus TK
gene have been proposed in combination with ACV or its
analogues as anti-cancer agents in suicide gene therapy.
However, the use of a virus in patients raises ethical concerns,
and is undermined by the risk of low and transient expression
levels of the transgene [16,17]. We previously have shown in
pancreatic cancer the efﬁcacy of acycloguanosyl 50-thymidyltri-
phosphate (ACV-TP-T), an ACV-derived pro-drug that is
constituted by a thymidine triphosphate attached to the hydroxyl
group of ACV [18]. This evidence together with the knowledge of
the important role of telomerase in HCC prompted us to test the
anti-neoplastic effect of this pro-drug against liver cancer.
In this paper we now provide direct evidence from both
in vitro analyses and in vivo experiments in HCC cells that ACV-
TP-T is actually a telomerase substrate, which by incorporating
the thymine base in DNA synthesis releases the acyclovir active
form. Importantly, we ﬁnd that ACV-TP-T treatment inhibits
tumour growth both in in vitro and in vivo models of
hepatocarcinogenesis.
Materials and methods
Detailed information on the experimental procedures are provided in the Supple-
mentary material and methods.Journal of Hepatology 2014Results
ACV-TP-T effects on hepatocellular cancer cell lines
Based on the evidence of increased telomerase activity in HCC tis-
sues compared to normal liver [19], human (HepG2, Hep3B, and
HuH7) and mouse (Hepa1-6) hepatocellular cancer cell lines
were exposed to increasing concentrations of ACV-TP-T (from
0.1 to 1000 lmol/L) for 24 h. ACV-TP-T inhibited DNA synthesis
in a dose-dependent manner in all tested cell lines and the calcu-
lated half maximal inhibitory concentration (IC50) ranged from 3
to 30 lmol/L (Table 1). Telomerase activity was also tested, and
as expected, telomerase activity was present in all liver cancer
cell lines analysed and its level was comparable to that of other
cancer cell lines from different tissues (data not shown). Interest-
ingly, normal cells derived from healthy human colon, 18CO,
showed no presence of telomerase activity and, as expected,
ACV-TP-T had no effect on viability or DNA synthesis.
In vitro activation of ACV-TP-T by telomerase
To demonstrate that ACV-TP-T is a telomerase substrate (Supple-
mentary Fig. 1) and that its effect on cancer cell lines depends on
its enzymatic activation of the pro-drug,we performed a direct tel-
omerase activity assay using partly puriﬁed telomerase from a
super-telomerase cell line [20] and decreasing concentrations of
ACV-TP-T. Fig. 1A clearly shows that ACV-TP-T is used by telome-
rase as a substrate in place of dTTP. To investigate, whether telo-
mere synthesis and incorporation of ACV-TP-T by the telomerase
releases ACV-DP, the telomere synthesis reaction was analysed
by chromatography. The analysis of the telomerase reaction after
6 h of incubation shows that whereas the concentration of
ACV-TP-T decreased by about 30%, a new peak representing
the formation of about 30% ACV-DP was formed (Fig. 1B). No
other products, such as ACV-TP, ACV-MP, or mono-, di- or tri-
phosphorylated dT, were found in appreciable quantities. Taken
together, these results conﬁrm that telomerase functions as an
activator of the pro-drug, through telomerase-dependent DNA
synthesis with a concomitant release of ACV-DP.
Next, we determined the telomerase Km values for ACV-TP-T
and dTTP. We estimated a Km value for ACV-TP-T of 3.6 mM,
which is approximately 50 times higher than the Km of the reac-
tion with dTTP (Fig. 1C and D). As the physiological concentration
of dTTP is in the low micromolar range [21], achieving thevol. 61 j 1064–1072 1065
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Fig. 1. ACV-TP-T can substitute dTTP as substrate for telomerase. (A) DNA synthesis by telomerase was analysed on denaturing PAGE. Lane 1: Partially puriﬁed
telomerase was incubated for 6 h at 37 C in the presence of 0.25 lM telomeric (TTAGGG) 3 primer, 1 mM dTTP, 1 mM dATP, 0.1 mM dGTP, and 0.17 lM dGTP [a-32P]; lane
2: reaction conditions as in lane 1 but without dTTP; lanes 3–6: conditions as in lane 1 but dTTP was substituted with 2 mM, 1 mM, 0.1 mM or 0.02 mM ACV-TP-dT
respectively. (B) Chromatographic analysis of telomerase reaction products under conditions as in (A), lane 3 (upper line); as a control, the reaction mix was incubated in
the absence of telomerase (lower line). ACV-DP is not present in the mediumwithout telomerase. In the presence of telomerase, ACV-TP-T is hydrolysed (about 30%) leading
to the formation of ACV-DP. (C) Telospot time courses where super-telomerase was incubated with 300, 320, 340, 360, 380 lM of ACV-TP-dT or 20, 40, 60, 80, 100 lM dTTP.
All other reaction components were kept as in (A). Reactions with ACV-TP-T were quenched after 30, 60, 90, 120, 150 min and reactions with dTTP after 10, 20, 30, 40,
45 min. 0.5 ll out of each 20 ll reaction were manually spotted 4 times on a nylon membrane, which was then probed with a randomly radiolabelled telomeric DNA.
Reaction products were quantiﬁed upon exposure of the membrane to a Phosphorimager. (D) Double reciprocal Lineweaver–Burk plots of initial velocities as determined
from panel (C). (E) LC-MS/MS analysis of cell lysates after an incubation time of 2 h (left panel) and 6 h (right panel). The total ion current (top panel) and the ion current
from the sum of two major fragment ions of each molecule of interest (lower panels) and their absolute intensities (NL) are shown. (F) LC-MS/MS analysis of genomic DNA
from Hepa1-6 cells after an incubation time of 6 h (panel E); DNA was puriﬁed and extensively degraded.
Research Article
1066 Journal of Hepatology 2014 vol. 61 j 1064–1072
JOURNAL OF HEPATOLOGY
optimal high micromolar values of the ACV-TP-T concentration
in vivo would ensure sufﬁcient selection of the pro-drug by the
telomerase.
HCC cells metabolize ACV-TP-T in vitro
To demonstrate that the activation of the pro-drug occurs in
hepatocellular cancer cells, Hepa1-6 cells were incubated for
2 h or 6 h with ACV-TP-T (1 mmol/L). Intracellular phosphory-
lated metabolites were characterized by LC-MS/MS (Fig. 1E).
When cells were treated for 2 h, analysis of the cellular extract
showed the presence of peaks corresponding to the pro-drug
and its metabolite ACV-DP. After 6 h, the concentration of ACV-
TP-T was decreased in the cells (39%) as well as in the culture
medium (14%). Interestingly, ACV-P and dTMP were increased
but the ACV active metabolite, ACV-DP, was reduced, suggesting
that it was actively incorporated into the DNA after further phos-
phorylation. Furthermore, after genomic DNA puriﬁcation and
degradation, we were able to identify ACV-P in the DNA sample
(Fig. 1F). These results demonstrate the ability of ACV-TP-T to
enter hepatoma cells and that the pro-drug is actively metabo-
lized inside the cells releasing the active species of ACV.
hTERT modulation inﬂuences HCC cell susceptibility to ACV-TP-T
To conﬁrm the role of telomerase in ACV-TP-T activation and
on the correlated effect on cell growth, we modulated
telomerase activity in HCC cells by transfection with wild type
(hTERT-WT) or dominant negative (hTERT-DN) hTERT expression
vectors. As shown in Supplementary Fig. 2, hTERT-DN overex-
pression in Hepa1-6 and HepG2 cells reduces telomerase
activity (43% ± 3 SEM and 66% ± 2 SEM, respectively) and in
parallel increases the IC50, indicating a lower susceptibility to
the drug. On the contrary, increasing telomerase activity by
hTERT-WT overexpression in the same cells brings a reduction
of ACV-TP-T IC50 (37% ± 2 SEM and 89% ± 12 SEM, respectively).
Differently, in Hep3B cells that have a high telomerase basal
activity (Table 1), hTERT–WT transfection had a negligible effect
on the susceptibility to ACV-TP-T, whereas hTERT-DN transfection
signiﬁcantly reduced telomerase activity and increased the
IC50. On the contrary, only hTERT–WT overexpression
signiﬁcantly inﬂuenced the susceptibility to ACV-TP-T in HuH7
transfected cells.
Similar experiments of telomerase modulation were done in
18CO, a normal cell line with no telomerase activity; the overex-
pression of hTERT-WT in this cell line was not able to reduce the
IC50 (>1000 lM) and this corresponded to a lack of restored telo-
merase activity even if hTERT mRNA levels were increased (data
not shown). When the cells were transfected with hTERT-hTR
the telomerase activity increased to 483 relative telomerase
activity (RTA) and the cells responded to ACV-TP-T with an IC50
of 177 lM.
Furthermore, to conﬁrm the role of telomerase in pro-drug
activation, Hepa1-6 cells were treated with other ACV derivatives
in which the thymidine was replaced with different bases. In
agreement with our previous results [18] the thymidine-linked
acyclovir (ACV-TP-T) was the most anti-proliferative drug and
the cytosine derivative (ACV-TP-C) did not inhibit proliferation,
consistently with the inability of telomerase to use cytosine as
substrate (Table 2). These results indicate the lack of non-speciﬁc
activity of the pro-drug.Journal of Hepatology 2014ACV-TP-T inhibits cancer cell proliferation by blocking cell cycle and
increases apoptosis
To evaluate whether the evident inhibition of cell proliferation
was associated with cell cycle modiﬁcation, FACS analysis of
Hepa1-6 cells treated with ACV-TP-T was performed at different
time points. ACV-TP-T treatment at the IC50 concentration
induced a signiﬁcant arrest in S-phase that was already evident
after 24 h (+37.7%) (Fig. 2A). This effect was consistently main-
tained at all experimental time points with an increased percent-
age of S-phase arrest in ACV-TP-T treated cells (p <0.001).
Moreover, ACV-TP-T treatment was able to increase the number
of apoptotic cells over time and FACS analysis by Annexin V/pro-
pidium iodide staining showed a peak at 72 h (Fig. 2B) with
18.7% ± 2.1 non-vital cells vs. 5.6% ± 0.9 in controls (p <0.001).
The capacity of ACV-TP-T to induce S-phase arrest was also
conﬁrmed in human cancer cell lines (HuH7 and Hep3B)
(p <0.01) (Supplementary Fig. 3). Analysis of dead cells in treated
and untreated HuH7 and Hep3B cells showed similar effects of
ACV-TP-T in the HuH7 cell line (Supplementary Fig. 4A)
(p <0.001), but unexpectedly Hep3B cells did not respond to
ACV-TP-T exposition. Considering that Hep3B are p53-null cells
and that this protein is a key regulator of the apoptotic process,
we reintroduced wild type p53 in Hep3B cells by transfection
with the pSN3-p53 vector [22]. Pro-apoptotic effects of ACV-TP-
T treatment after 48 h and 72 h were signiﬁcantly (p <0.01)
increased in pSN3-p53-transfected Hep3B but not in Hep3B cells
transfected with the control vector, indicating that p53 is neces-
sary to promote cell death by ACV-TP-T (Supplementary Fig. 4B).
ACV-TP-T induced HCC regression in HBV transgenic mice
Following the in vitro results we chose to examine the effect of
ACV-TP-T administration in a mouse model of HBV-related
hepatocarcinogenesis. Hepatocytes of HBV transgenic mice (Tg
[Alb-1 HBV] Bri 44) express and accumulate the large HBsAg pro-
tein, resulting in severe chronic hepatocellular injury. This condi-
tion is always followed by the development of dysplastic hepatic
lesions that progress after the 9 months to hepatocellular adeno-
mas and carcinomas [23,24]. Interestingly, livers of 15-month old
mice that have large tumours have increased telomerase activity
compared to wild type animals (Supplementary Fig. 5). ACV-TP-T
or vehicle alone (control) were administered three times per
week by i.p. injection to HBV transgenic mice (n = 40) for 4 weeks
starting from 15 months when all animals have developed
hepatocellular adenomas and hepatocellular carcinomas.
ACV-TP-T-treated mice showed signiﬁcantly smaller neoplastic foci
compared with vehicle-treated animals. In parallel, a-fetoprotein, a
marker of hepatocellular regeneration and transformation, was
drastically reduced in ACV-TP-T-treated animals. The growth
inhibition and the possible induction of tumour regression by
ACV-TP-T correlated with the reduction of the proliferative activ-
ity and increased frequency of apoptotic liver cells as measured
by immunostaining detection of PCNA and activated caspase 3,
respectively (Fig. 3).
Growth inhibition induced by ACV-TP-T evaluated in an orthotopic
syngeneic mouse model of HCC
We next assessed the impact of ACV-TP-T alone or in association
with the multikinase inhibitor Sorafenib on tumour growth in anvol. 61 j 1064–1072 1067
Table 2. In vitro effects of ACV-TP-G, ACV-TP-A, ACV-TP-T and ACV-TP-C.
Hepa 1-6 Nucleotide analogs
ACV-TP-G ACV-TP-A ACV-TP-T ACV-TP-C 
Viability (IC50 μM) 150 300 >1000 >1000 
DNA synthesis (IC50 μM) 1000 120 2 >1000 
The four compounds were tested on Hepa1-6 cells measuring both viability (based on ATP concentration) and proliferation (based on thymidine incorporation).
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Fig. 2. ACV-TP-T treatment blocks HCC mouse cells in S-phase and increases cell death. (A) Cell cycle analysis of synchronized Hepa1-6 cells treated with ACV-TP-T:
data showing one representative experiment out of three with the distribution of cells in G0G1, S-phase, G2M. Inset: cell morphology at 72 h. (B) Flow cytometry analysis of
Hepa1-6 cell vitality at 24 h, 48 h and 72 h (one representative experiment out of three): apoptotic and dead cells are expressed as% of total events.
Research Articleorthotopic mouse model. We implanted 2  106 Hepa1-6 cells in
C57Bl/6 mice (n = 40). After 2 weeks of treatment we measured
macroscopically the major diameter of the formed tumours,
and microscopically the total surface area of the left lobe occu-
pied by cancer cells (Fig. 4). Interestingly, the size and relative1068 Journal of Hepatology 2014surface area occupied by the tumours were signiﬁcantly
decreased in all treated animals compared to control animals
whose liver left lobe was largely replaced by tumour cells. No sta-
tistical difference was found among the three treated group
(ACV-TP-T alone, Sorafenib alone or in combination). During thevol. 61 j 1064–1072
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Fig. 3. ACV-TP-T treatment reduces neoplastic lesion size in a transgenic
spontaneous hepatic tumour mouse model. (A) Representative image of the
livers for control and ACV-TP-T treated mice. Tumour cells were identiﬁed
following H&E staining (100magniﬁcation). Proliferation was assessed by PCNA
antibody staining, apoptosis by activated Caspase 3 antibody staining. (B) The
macroscopic tumours were identiﬁed at the time of sacriﬁce; the maximum
diameter (cm) was measured with a caliper (⁄⁄p <0.01). (C) Quantiﬁcation of
a-fetoprotein level in the serum of the animals at the time of sacriﬁce (expressed
as average ± SD, ⁄p <0.05). (D) Quantiﬁcation of PCNA labelling index (expressed
as average ± SEM, ⁄⁄p <0.01). (E) Quantiﬁcation of activated Caspase 3 positive
cells (expressed as average ± SEM, ⁄p <0.05).
JOURNAL OF HEPATOLOGYtreatment no adverse events were detected in the ACV-TP-T
group, but a few deaths occurred within the ﬁrst week in the
Sorafenib alone (n = 1) and in the combination group (n = 3).Journal of Hepatology 2014Discussion
In the last decade, telomerase activation and its regulation have
become a topic of intense investigation in oncology and aging-
related diseases [25–27]. Activation of telomerase seems to be
one of the crucial events that underlie the multigenetic process
of carcinogenesis [12,28]. In the ﬁeld of HCC where the discovery
of new systemic therapies is urgently needed, the well-
characterized key role of telomerase in hepatocarcinogenesis
makes this enzyme an attractive therapeutic target [29–31].
Several different approaches are being investigated to target
telomerase. Direct inhibition of the catalytic subunit (hTERT) or
its RNA template (hTER), using small molecules, antisense oligo-
nucleotides or immunotherapy, have been proposed. Other inves-
tigators have suggested to target telomerase activity indirectly
with compounds that stabilize the DNA G-quadruplex, that inhi-
bit telomere synthesis, tankyrase or HSP90 inhibitors, thus block-
ing telomerase access to telomeres or inhibiting binding of
telomerase-associated proteins [32,33]. Furthermore, telomerase
gene transcription in cancer was also proposed in suicide gene
therapy where Herpes simplex virus thymidine kinase (TK),
expressed under control of the telomerase promoter, was associ-
ated with ganciclovir treatment [34].
The therapeutic approach targeting telomerase presented in
this study is innovative: it uses native cancer cell telomerase
enzymatic activity to transform a pro-drug into an active mole-
cule that blocks DNA synthesis necessary for cell proliferation
in cancer cells. We showed that the telomerase of HCC cells
metabolizes the pro-drug and releases an active form of ACV that
is responsible for the inhibition of HCC cell proliferation both in
in vitro and in vivo models of hepatocarcinogenesis. All HCC cell
lines tested were susceptible to the anti-proliferative effect of
ACV-TP-T, although the response in term of cell growth inhibition
was slightly different between the different cell lines (Table 1).
Our evidence suggests that susceptibility to ACV-TP-T in HCC
cells might be inﬂuenced by other mechanisms. The expression
of nucleoside transporters, DNA repairing systems, kinase expres-
sions and multidrug resistant proteins might play a key role in
the susceptibility and resistance of cancer cells to nucleoside ana-
logues. These pathways have already been described in HCC
[35,36] and are currently under investigation in our laboratory.
Nevertheless, we clearly demonstrated that ACV-TP-T was a telo-
merase substrate and that hepatocellular cancer cells took up and
metabolized ACV-TP-T to release the active compound (Fig. 1E).
Unexpectedly, a lower efﬁciency of telomere synthesis was
observed at a higher concentration of ACV-TP-T in the in vitro
enzymatic reaction (Fig 1A, compare lane 3 and 5). A possible
explanation could be that in the presence of high concentrations
of ACV-TP-T, telomerase might use the pro-drug from the ACV-TP
side to incorporate ACV-MP in place of dG-MP, thereby interrupt-
ing telomere synthesis and therefore preventing further process-
ing of the pro-drug [20]. In any case, these high concentrations
are not relevant in vivo, and therefore this effect is of little con-
cern for the possible in vivo use of the pro-drug. The role of telo-
merase in pro-drug activation was further conﬁrmed in HCC cell
cultures by the overexpression of the wild type or the dominant
negative genes of hTERT, which reduced or increased ACV-TP-T
efﬁcacy in parallel with the variation of the telomerase activity
levels (Supplementary Fig. 2).
In agreement with previous studies that reported an S-phase
cellular arrest and induction of cell death after ACV treatmentvol. 61 j 1064–1072 1069
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Fig. 4. Decreased growth of implanted Hepa1-6 cells with ACV-TP-T and/or Sorafenib treatment. (A) Representative images of the left lobe of the livers for each group.
Tumour cells were identiﬁed following H&E staining (100magniﬁcation). Proliferation was assessed by PCNA antibody staining, apoptosis by activated Caspase 3 antibody
staining. (B) The macroscopic tumours were identiﬁed at the time of sacriﬁce; the maximum diameter (cm) was measured with a caliper (⁄p <0.05). (C) Tumour surface was
estimated in the left lobe of each liver by direct measurement, and the surface ratio between the tumour and the lobe was quantiﬁed with an image analyser (BioQuant
Software) (expressed as average ± SEM; ⁄⁄p <0.01).
Research Article[37,38] in infected cells, ACV-TP-T induced a block in the cell
cycle, and increased the number of apoptotic cells (Fig. 2 and
Supplementary Figs. 3 and 4). Besides, in Hep3B cells that are
p53-null we were able to induce cellular arrest, but not cell death.
The reintroduction of p53 in this cell line increased the number of
pro-apoptotic cells similarly to the other cell lines, indicating that
p53 is necessary for the activation of the pro-apoptotic pathway.
Interestingly, the treatment with ACV-TP-T in cell lines where
p53 is mutated or missing (HuH7 and Hep3B, respectively), mim-
icking HCC cells in which the p53 pathway is often lacking due to
frequent mutations [39], was consistently able to induce cellular
arrest. In consideration of the selective effects on cancer cells
these data suggest that this molecule could be used alone for
its cytostatic effect or in combination therapies.1070 Journal of Hepatology 2014As shown in our previous study [18], four week treatment
with ACV-TP-T was able to reduce the growth of pancreatic ade-
nocarcinoma sparing the healthy proliferating tissues, suggesting
that this pro-drug has a highly selective activity on cancer cells
that have reactivated telomerase and might be safe for the treat-
ment of patients.
Here we also demonstrated that ACV-TP-T had anti-prolifera-
tive and pro-apoptotic effects on hepatocellular cancer cells
in vivo: in only four weeks it was able to block the progression
of the hepatic lesions and induced regression of spontaneously
developed tumours in a transgenic model (Fig. 3). Furthermore,
the treatment was able to reduce the growth of murine HCC cells
directly implanted in the liver of wild type syngeneic animals,
which in two weeks can reach over 1 cm in diameter in untreatedvol. 61 j 1064–1072
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animals (Fig. 4). This evidence strongly suggests the possible use
of this molecule for the treatment of HCC, as well as for all
pre-neoplastic or cancer lesions with high telomerase activity
[40–44]. The effects obtained in the orthotopic syngeneic model
also indicate that a combination of ACV-TP-T therapy targeting
telomerase activity with the approved standard of care,
Sorafenib, is possible and, even if it is not reaching a statistical
signiﬁcance against each single treatment, reduces the average
diameter of nodules and the microscopical extension of cancer
cell replacement of normal liver tissues (Fig. 4B and C).
In conclusion the mechanism of selective telomerase activa-
tion of the pro-drug holds great promise for the treatment of
hepatocellular cancer and of other tumours characterized by high
telomerase expression.Financial support
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